Immune checkpoint inhibitors that block PD-1 and CTLA4 have been indicated to be efficient in the therapy of ccRCC and can be used as standard therapy (Motzer et al., 2018). This evidence concerns the gene CTLA4 and nonpapillary renal cell carcinoma.